Scailyte’s AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manufacturing success where standard analysis methods failed, creating an actionable solution to de-risk cell therapy production.
Continue reading
Project AIomics will unite Scailyte’s AI discovery platform with the Swiss IBD Cohort and Universitätsspital Zürich to predict patient response to biologic therapies, uncover resistance mechanisms, and identify novel drug targets.
Continue reading
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.
Continue reading
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Darrin Crisitello as member of the BoD.
Continue reading
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings strong expertise in computational biology, immunology, and cancer research, with a track record of high-profile publications.
Continue reading
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million.
Continue reading
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI landscape.
Continue reading
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their collaboration to improve patient outcomes.
Continue reading
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is proud to announce the appointment of Jan Lichtenberg to its Board of Directors.
Continue reading
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunities for innovation in endometriosis”.
Continue reading
